FDA decision delayed on Biojector for administering T-20 pending additional safety information
7 October 2006. Related: Antiretrovirals.
2006
BHIVA draft report on UK standards for HIV care (2006)
7 October 2006. Related: Guidelines.
US adult treatment guidelines updated (2006)
7 October 2006. Related: Guidelines.
Gilead licenses tenofovir to Indian generic manufacturers
7 October 2006. Related: Treatment access.
Funding prospects improve for Round 6 Global Fund
7 October 2006. Related: Treatment access.
Extensively drug resistant tuberculosis: a serious wake-up call for global health
7 October 2006. Related: TB coinfection, Other news.
Global report on TB and HIV: new analysis of TB/HIV epidemics in Bangladesh, Brazil, Nigeria, Tanzania, and Thailand
7 October 2006. Related: TB coinfection, Other news.
Viral load is a poor predictor of CD4 decline at the individual level
7 October 2006. Related: Basic science and immunology.
Volume 7 Number 10 October 2006 PDF
1 October 2006. Related: PDFs.
Volume 7 Number 9 September 2006
30 September 2006. Related: Editorial.
XVI International AIDS Conference, Toronto, Canada. 13-18 August 2006
15 September 2006. Related: Conference reports.
Enough is enough: South African activists demand: fire Manto
10 September 2006. Related: Conference reports, Treatment access.
Treatment access: more optimistic results from scale up programmes
10 September 2006. Related: Conference reports, Treatment access.
Integrase inhibitor MK-0518: early results show greater early potency than efavirenz
10 September 2006. Related: Conference reports, Antiretrovirals.
Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect
10 September 2006. Related: Conference reports, Antiretrovirals.
Vicriviroc 24-week results in triple-class experienced R5-tropic patients
10 September 2006. Related: Conference reports, Antiretrovirals.
Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355
9 September 2006. Related: Conference reports, Antiretrovirals.
New data on darunavir (TMC-114)
9 September 2006. Related: Conference reports, Antiretrovirals.
Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance
9 September 2006. Related: Conference reports, Antiretrovirals.
Atazanavir/r monotherapy and CNS penetration
9 September 2006. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks
9 September 2006. Related: Conference reports, Antiretrovirals.
Children face a serious service delivery gap: paediatric studies in Toronto
9 September 2006. Related: Conference reports, Paediatric care.
Bioavailability study results for new paediatric tablets for oral suspension, and caution against splitting adult doses
9 September 2006. Related: Conference reports, Paediatric care.
Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) Trial
9 September 2006. Related: Conference reports, Paediatric care.
3TC/abacavir maintains virological superiority over AZT/3TC and AZT/abacavir beyond 5 years in children
9 September 2006. Related: Conference reports, Paediatric care.
French study raises importance of early screening for anal cancer in HIV-positive people
9 September 2006. Related: Conference reports, Coinfections and complications, Cancer and HIV.
Prognostic index for risk of progression of Kaposis Sarcoma
9 September 2006. Related: Conference reports, Coinfections and complications.
Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin
9 September 2006. Related: Conference reports, Side effects, Cancer and HIV.
Selected abstracts from Track A presentations at Toronto
9 September 2006. Related: Conference reports, Basic science and immunology.
Use of complementary alternative medicine that could interact with ARV treatment reported by 20% patients in the UK
9 September 2006. Related: Conference reports.
Poor scientific or medical knowledge is a factor in increase in criminal charges for HIV transmission in the UK
9 September 2006. Related: Conference reports.
Treatment access and community responses: online webcasts and debates
9 September 2006. Related: Conference reports, Treatment access.
Patent oppositions filed on three essential drugs
9 September 2006. Related: Treatment access.
WHO guidelines for ARV treatment in resource limited settings (2006)
9 September 2006. Related: Guidelines.
Antiretroviral effect of foscarnet in patients with multiple drug resistance in late stage HIV disease
9 September 2006. Related: Antiretrovirals.
AIDS issue of the British medical journal The Lancet online
9 September 2006. Related: On the web.
TAG pipeline drugs report: July 2006
9 September 2006. Related: On the web.
OSI/TAG report on civil society involvement in TB/HIV
9 September 2006. Related: On the web.
Tuberculosis R&D Investments: A Preliminary Assessment
9 September 2006. Related: On the web.
Resource for HIV-positive travellers: HIV/AIDS regulations
9 September 2006. Related: On the web.
Volume 7 Number 9 September 2006 PDF
1 September 2006. Related: PDFs.
Volume 7 Number 7/8 July/August 2006
25 August 2006. Related: Editorial.
Dear Doctor letter issued in the U.S. relating to 14 reports of intracranial haemorrhage (ICH) events with tipranavir/r
3 August 2006. Related: Treatment alerts.
15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain
3 August 2006. Related: Conference reports, Drug resistance.
Resistance implications of monotherapy with lopinavir/r (Kaletra)
3 August 2006. Related: Conference reports, Drug resistance.
Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir
3 August 2006. Related: Conference reports, Drug resistance.
Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
3 August 2006. Related: Conference reports, Drug resistance.
Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation?
3 August 2006. Related: Conference reports, HIV prevention and transmission, Drug resistance.
K103N containing variants persist longer in women with subtype D and with higher viral loads
3 August 2006. Related: Conference reports, Drug resistance.
No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
3 August 2006. Related: Conference reports, Drug resistance.
Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women
3 August 2006. Related: Conference reports, Drug resistance.
High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
3 August 2006. Related: Conference reports, Drug resistance.
Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates
3 August 2006. Related: Conference reports, Drug resistance.
Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings
3 August 2006. Related: Conference reports, Drug resistance.
Limitations in online tools to identify HIV-1 subtypes
3 August 2006. Related: Conference reports, Drug resistance.
Resistance implications from PrEP and microbicide studies in macaques
3 August 2006. Related: Conference reports, Drug resistance.
Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients
3 August 2006. Related: Conference reports, Drug resistance.
Testing for resistance after starting treatment
3 August 2006. Related: Conference reports, Drug resistance.
New formulation of lopinavir/r approved in Europe (Kaletra) and new tradename for access countries (Aluvia)
3 August 2006. Related: Antiretrovirals.
US approval for darunavir (TMC-114, Prezista)
3 August 2006. Related: Antiretrovirals.
Boehringer stops tipranavir trial in treatment-naive patients
3 August 2006. Related: Antiretrovirals.
FDA approves fixed-dose combination of efavirenz/tenofovir/FTC (Atripla): joint company collaboration produces once-daily one pill combination
3 August 2006. Related: Antiretrovirals.
Evidence that CCR5 is protective against West Nile virus: implications for CCR5 inhibitors
3 August 2006. Related: Antiretrovirals.